Procaps Group, SA announces the expansion of its oncology portfolio

Procaps Group, SA announces an agreement with BDR Pharmaceuticals International Pvt. Limited to 27 oncology molecules for Latin America, including 20 TKIs (Tyrosine Kinase Inhibitors). Under the deal, Procaps will be responsible for registration, branding, marketing and commercialization throughout Latin America.

Procaps has submitted an initial batch of 8 molecules to the regulatory body in Colombia and plans to later expand to other parts of Latin America. Oncology is one of the most relevant therapeutic areas worldwide, a growing trend in Latin America driven by aging and population growth and improvements in cancer survival rates. According to the International Agency for Research on Cancer, cancer rates in Central and South America are expected to increase by 91.4% and 76.5%, respectively, by 2040, mainly due to lifestyle factors, aging population, screening and infection-related cancers.

The Latin American regions where Procaps operates have a total population of approximately 204 million people, and the incidence of cancer affects approximately 0.3% of the population, which equates to approximately 500,000 new cases per year.